At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
NutriDrink +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Influence of Enteral Nutrition on Functional Status and Inflammatory Activation in Patients With Congestive Heart Failure and Cardiac Cachexia.
In Brief
A Phase 2 clinical trial evaluating NutriDrink and Placebo for Chronic Heart Failure and Cardiac Cachexia. Completed, enrolled 29 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study was to determine the effects of a high caloric drink on weight and several other clinical markers including quality of life in patients with unintentional weight loss (cachexia) due to chronic heart failure.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Heart Failure, Cardiac Cachexia
CountriesGermany, Poland
CollaboratorsNutricia Research Fundation
Timeline
Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2001
Primary CompletionFeb 2002
First PostedApr 2008
TodayJul 2026
First PostedApr 9, 2008
Enrollment StartApr 1, 2001
Primary CompletionFeb 1, 2002
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.2 years ago
Interventions
NutriDrinkdietary
Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
Placebodietary
Nutritional supplementation containing only 12 kcal/day